Voxcan

Voxcan is a Lyon, France based startup specializing in non-invasive high-resolution imaging for non-clinical drug development. With a 16-year track record, their core focus areas include oncology, viral and bacterial infectious diseases, osteo-articular inflammatory diseases, and medical devices. The company's expertise lies in conducting efficacy, biodistribution, mechanistic, and proof of concept studies based on in vitro and in vivo models combined with high-resolution imaging in small animal species. In July 2023, Voxcan became part of the ERBC group, broadening its service offerings and providing clients with access to a full range of non-clinical expertises. This acquisition aligns with ERBC's 3R policy, aiming to reduce the number of animals (up to 80%) used in non-clinical studies and improve animal welfare. Voxcan's capability to perform non-clinical studies up to Biosafety Level 3, meeting stringent safety and containment requirements in the infectious disease domain, is a testament to their commitment to scientific reliability and traceability. Moreover, Voxcan offers a wide variety of characterized tumor, bacterial, and viral models, including SARS-CoV-2, to test new compounds and cell therapies, as well as assess medical device performance and degradation. Their expertise in non-clinical 3D CT (computed tomography) imaging, 3D high-resolution imaging (µCT), and non-invasive bioluminescence and fluorescence imaging, combined with mechanistic analyses based on technologies such as flow cytometry, Luminex, and qPCR, enables longitudinal monitoring of compound efficacy and biodistribution. Ultimately, Voxcan aims to assist Pharma, Biotech, and Medical Device companies in accelerating the time-to-market of their candidate therapies by providing high-technology readouts. With a solid foundation since 2007 and strategic integration within the ERBC group, Voxcan is well-positioned to drive innovation and contribute meaningfully to the field of non-clinical drug development.